Gleevec/Glivec

Seismic shifts: Hepatitis C and payers

Analogues such as Glivec (imatanib) which transformed outcomes in CML need to be utilised to demonstrate that tough investment decisions by payers do pay off.

NICE overturns negative Glivec guidance

Novartis has since provided more evidence supporting the use of the drug, known as Gleevec in certain regions. ... Glivec is Novartis' biggest selling pharmaceutical product, taking in in nearly $4.7bn during 2013.

India has big plans for healthcare and pharma

A number of court cases are proceeding and earlier this year the Indian Supreme Court denied Novartis patent protection for its cancer drug Glivec.

Bayer wins GIST approval for Stivarga in EU

Cancer drug can be used after Pfizer’s Sutent and Novartis’ Glivec. ... Patients must have progressed on - or must be intolerant to - prior treatment with Novartis' Glivec (imatinib) and Pfizer's Sutent (sunitinib) and the European Commission

Novartis' vaccine sales decline ahead of GSK transfer

for cancers affecting the bone and the start of generic competition to leukaemia therapy Glivec (imatinib). ... The first generic for Glivec is due in the US market in February 2016, although Novartis is hopeful that the oncology portfolio due to be

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]